UA110343C2 - Spiro heterocyclic compounds as antagonists mglur5 - Google Patents
Spiro heterocyclic compounds as antagonists mglur5Info
- Publication number
- UA110343C2 UA110343C2 UAA201301071A UAA201301071A UA110343C2 UA 110343 C2 UA110343 C2 UA 110343C2 UA A201301071 A UAA201301071 A UA A201301071A UA A201301071 A UAA201301071 A UA A201301071A UA 110343 C2 UA110343 C2 UA 110343C2
- Authority
- UA
- Ukraine
- Prior art keywords
- treatment
- compounds
- carbon atom
- urinary tract
- lower urinary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36294410P | 2010-07-09 | 2010-07-09 | |
PCT/EP2011/061690 WO2012004400A1 (en) | 2010-07-09 | 2011-07-08 | Novel spiroheterocyclic compounds as mglu5 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
UA110343C2 true UA110343C2 (en) | 2015-12-25 |
Family
ID=44503767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201301071A UA110343C2 (en) | 2010-07-09 | 2011-08-07 | Spiro heterocyclic compounds as antagonists mglur5 |
Country Status (17)
Country | Link |
---|---|
US (1) | US8580962B2 (ru) |
EP (1) | EP2590985B1 (ru) |
JP (1) | JP2013529673A (ru) |
KR (1) | KR101862626B1 (ru) |
CN (1) | CN103097391B (ru) |
AU (1) | AU2011275696B2 (ru) |
BR (1) | BR112013000529B1 (ru) |
CA (1) | CA2800930C (ru) |
EA (1) | EA023020B1 (ru) |
ES (1) | ES2492694T3 (ru) |
HK (1) | HK1179248A1 (ru) |
IL (1) | IL223330A (ru) |
MX (1) | MX2013000300A (ru) |
NZ (1) | NZ603868A (ru) |
SG (1) | SG186107A1 (ru) |
UA (1) | UA110343C2 (ru) |
WO (1) | WO2012004400A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
EA035237B1 (ru) * | 2014-12-29 | 2020-05-19 | Рекордати Айерленд Лимитед | ПРОИЗВОДНЫЕ ГЕТЕРОЦИКЛИЛАЛКИНОВ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ МЕТАБОТРОПНЫХ ГЛУТАМАТНЫХ РЕЦЕПТОРОВ 5-ГО ПОДТИПА (mGluR5) |
JP6603334B2 (ja) | 2015-06-03 | 2019-11-06 | エフ.ホフマン−ラ ロシュ アーゲー | エチニル誘導体 |
CN107903265A (zh) * | 2017-11-21 | 2018-04-13 | 毛琳琳 | 一种新型螺环类杀虫剂的制备方法及应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW593241B (en) * | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
US6548522B1 (en) * | 1999-10-12 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives |
EP1230225A2 (en) | 1999-11-01 | 2002-08-14 | Eli Lilly And Company | Pharmaceutically active 4-substituted pyrimidine derivatives |
BR0111747A (pt) | 2000-06-28 | 2003-07-08 | Smithkline Beecham Plc | Processo de moagem úmida |
US6369222B1 (en) * | 2000-07-18 | 2002-04-09 | Hoffmann-La Roche Inc. | mGluR antagonists and a method for their synthesis |
GB0322612D0 (en) * | 2003-09-26 | 2003-10-29 | Novartis Ag | Organic compounds |
GB0508318D0 (en) * | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
DE102005044813A1 (de) | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
JP2010503656A (ja) * | 2006-09-13 | 2010-02-04 | アストラゼネカ アクチボラグ | スピロ−オキサゾリジノン化合物と代謝共役型グルタミン酸受容体ポテンシエーターとしてのその使用 |
-
2011
- 2011-07-08 JP JP2013517409A patent/JP2013529673A/ja not_active Withdrawn
- 2011-07-08 MX MX2013000300A patent/MX2013000300A/es active IP Right Grant
- 2011-07-08 SG SG2012087912A patent/SG186107A1/en unknown
- 2011-07-08 EA EA201270799A patent/EA023020B1/ru not_active IP Right Cessation
- 2011-07-08 CN CN201180043746.5A patent/CN103097391B/zh not_active Expired - Fee Related
- 2011-07-08 WO PCT/EP2011/061690 patent/WO2012004400A1/en active Application Filing
- 2011-07-08 NZ NZ603868A patent/NZ603868A/en not_active IP Right Cessation
- 2011-07-08 CA CA2800930A patent/CA2800930C/en not_active Expired - Fee Related
- 2011-07-08 EP EP11746494.1A patent/EP2590985B1/en active Active
- 2011-07-08 BR BR112013000529-7A patent/BR112013000529B1/pt not_active IP Right Cessation
- 2011-07-08 KR KR1020137003488A patent/KR101862626B1/ko active IP Right Grant
- 2011-07-08 ES ES11746494.1T patent/ES2492694T3/es active Active
- 2011-07-08 AU AU2011275696A patent/AU2011275696B2/en not_active Ceased
- 2011-07-11 US US13/180,166 patent/US8580962B2/en not_active Expired - Fee Related
- 2011-08-07 UA UAA201301071A patent/UA110343C2/ru unknown
-
2012
- 2012-11-28 IL IL223330A patent/IL223330A/en active IP Right Grant
-
2013
- 2013-05-23 HK HK13106089.4A patent/HK1179248A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN103097391A (zh) | 2013-05-08 |
CA2800930A1 (en) | 2012-01-12 |
EA201270799A1 (ru) | 2013-05-30 |
IL223330A0 (en) | 2013-02-03 |
NZ603868A (en) | 2014-08-29 |
AU2011275696B2 (en) | 2016-02-11 |
US8580962B2 (en) | 2013-11-12 |
CN103097391B (zh) | 2015-04-08 |
CA2800930C (en) | 2018-08-21 |
KR101862626B1 (ko) | 2018-05-31 |
ES2492694T3 (es) | 2014-09-10 |
BR112013000529A2 (pt) | 2016-05-24 |
MX2013000300A (es) | 2013-02-27 |
US20120059015A1 (en) | 2012-03-08 |
SG186107A1 (en) | 2013-01-30 |
HK1179248A1 (en) | 2013-09-27 |
EA023020B1 (ru) | 2016-04-29 |
KR20130097153A (ko) | 2013-09-02 |
EP2590985A1 (en) | 2013-05-15 |
EP2590985B1 (en) | 2014-05-14 |
JP2013529673A (ja) | 2013-07-22 |
WO2012004400A1 (en) | 2012-01-12 |
AU2011275696A1 (en) | 2012-12-20 |
BR112013000529B1 (pt) | 2019-11-19 |
IL223330A (en) | 2015-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009237649B2 (en) | Indole modulators of the alpha 7 nicotinic acetylcholine receptor | |
AU2018282336A1 (en) | Trk-inhibiting compound | |
EA200601266A1 (ru) | Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата | |
MX2012003499A (es) | Inhibidores de demetilasa-1 especificos de lisina y su uso. | |
EA201400553A1 (ru) | Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида | |
JP2014506599A5 (ru) | ||
MY148694A (en) | Substituted benzimidazoles and methods of preparation | |
BR122019017036B8 (pt) | compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica | |
NO20075624L (no) | Nye histamin H3-reseptorligander og deres terapeutiske anvendelser | |
CY1110952T1 (el) | Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3 | |
CY1111651T1 (el) | Παραγωγα 3-(ετεροαρυλ-oξυ)-2-αλκυλ-1-αζα- δικυκλοαλκυλιου ως συνδετες του αλφα.7-nachr για τη θεραπεια των ασθενειων του κνς | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
CA2825134A1 (en) | Indole derivative, and pharmacologically acceptable salt thereof | |
MX2016006685A (es) | Compuestos heterociclicos de n-acilimino. | |
WO2017103604A1 (en) | Hydantoin modulators of kv3 channels | |
EA200800540A1 (ru) | Карбоксамидные производные в качестве антагонистов мускариновых рецепторов | |
NO20076424L (no) | N-koblete heterocykliske antagonister av P2Y1 reseptoren nyttige for behandling av tromboseforstyrrelser | |
NO20063747L (no) | Substituerte kinoliner og deres anvendelse som mykobakterielle inhibitorer | |
MX2009013115A (es) | Derivados de prolinamida como antagonistas de nk3. | |
UA110343C2 (en) | Spiro heterocyclic compounds as antagonists mglur5 | |
MX2007000576A (es) | Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias. | |
AR104837A1 (es) | Compuestos heterocíclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de nmda nr2b | |
ES2380165T3 (es) | Nuevos compuestos heterocíclicos como antagonistas mGlu5 | |
EA201001645A1 (ru) | Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора | |
MX2012001799A (es) | Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3). |